ArticleAnnals of hematology2026
Academic BCMA CAR-T (ARI0002h) achieves MRD-negative remission with sBCMA biomarker response in relapsed POEMS syndrome after double ASCT.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes (POEMS) syndrome is a rare plasma cell disorder with diverse multisystem manifestations. Autologous stem cell transplantation (ASCT) is the preferred front-line therapy when feasible, but relapsed/refractory (RR) cases after ASCT failure lack effective salvage options. B-cell maturation antigen (BCMA)-directed CAR-T cell therapy has revolutionised multiple myeloma (MM) treatment. Given the shared BCMA expression on clonal plasma cells between MM and POEMS, CAR-T cell therapy is also a biologically compelling strategy for POEMS syndrome [1]. However, there are only two previous case reports of CAR-T cell therapy in POEMS [3,4], none involving patients with prior ASCT failure. We report a 54-year-old male with RR-POEMS progressing after two previous ASCT failures who received an academic point-of-care BCMA-directed CAR-T cell therapy (ARI0002h) via fractionated infusion. No cytokine release syndrome (CRS) or neurotoxicity (ICANS) occurred. At 3 months, the patient achieved a measurable residual disease (MRD)-negative complete haematological response (CR
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.